<?xml version="1.0" encoding="UTF-8"?>
<p id="Par17">A total of 157 subjects (116 males and 41 females) were enrolled. Of these, 107 were HBV-infected, 54 receiving NAs (Group A) with a median duration of the current regimen of 48 months (Interquartile range, IQR 24–60) and with a median total therapy duration of 60 months (IQR 40–108), 53 were naïve to antiviral therapy (Group B), and 50 were age-sex matched HBV-HCV-HIV negative controls (Group C).</p>
